TCM
PCRX icon

Tradewinds Capital Management’s Pacira BioSciences PCRX Stock Holding History

Tradewinds Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-100
Closed -$5K – 693
2017
Q1 		$5K Buy
+100
New +$4.32K ﹤0.01% 494

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Tradewinds Capital Management's PCRX Position: Q2 2017 in Review

Tradewinds Capital Management sold out of Pacira BioSciences (PCRX) in Q2 2017, closing a stake of 100 shares — an estimated $5K sold.

Tradewinds Capital Management first reported a position in PCRX in Q1 2017 and held it in 1 quarter. The position peaked at $5K in Q1 2017. 196 funds tracked by Wall St. Rank hold PCRX as of Q2 2017.

  • Tradewinds Capital Management reported no remaining Pacira BioSciences position as of Q2 2017 after selling out during the quarter.
  • Tradewinds Capital Management sold 100 Pacira BioSciences shares in Q2 2017, an estimated $5K.
  • Tradewinds Capital Management first reported a position in Pacira BioSciences in Q1 2017 and held it in 1 quarter.
  • Tradewinds Capital Management's Pacira BioSciences position peaked at $5K in Q1 2017.
  • 196 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2017.

Based on Tradewinds Capital Management's 13F filing for Q2 2017, filed 1 Aug 2017.